Therapy for cutaneous T-cell lymphoma using low-dose bexarotene combined with phototherapy or alpha-interferon: Report of eight cases treated in Hospital Nacional Edgardo Rebagliati-Martins, Lima, Peru between 2003 and 2007

Authors

  • Brady Beltrán Gárate Hospital Edgardo Rebagliati Martins, Lima, Peru.
  • Antonio Paredes Arcos Hospital Edgardo Rebagliati Martins, Lima, Peru.
  • Celia Moisés Alfaro Hospital Edgardo Rebagliati Martins, Lima, Peru.
  • Gadwin Sanchez Félix Hospital Edgardo Rebagliati Martins, Lima, Peru.
  • Luis Riva Gonzales Hospital Edgardo Rebagliati Martins, Lima, Peru.
  • Fernando Hurtado de Mendoza Hospital Edgardo Rebagliati Martins, Lima, Peru.
  • Esther Cotrina Montenegro Departamento de Enfermería, Hospital Edgardo Rebagliati Martins. Lima, Peru.
  • Renzo Salas Rojas Departamento de Oncología-Radioterapia, Hospital Edgardo Rebagliati Martins, Lima, Peru.

Keywords:

Cutaneous T-cell lymphoma, bexarotene, alpha-interferon

Abstract

Introduction: Bexarotene is a rexinoid compound that is approved for use in the therapy for early and advanced stage cutaneous T-cell lymphoma (CTCL).
Clinical Cases: We present in this report the results of the use of low-dose bexarotene plus phototherapy or alpha-interferon, nine million units, in the treatment of CTCL. Eight patients were treated, five had mycosis fungoides, two had CD-8 epidermothropic aggressive lymphoma. The overall response rate was 62.5% (5/8), and the mean duration of response was 20 months. Low-dose bexarotene combined with phototherapy or alpha-interferon may be effective in the treatment of CTCL.

Downloads

Download data is not yet available.

Downloads

Published

2018-06-30

Issue

Section

CASE REPORTS

How to Cite

1.
Therapy for cutaneous T-cell lymphoma using low-dose bexarotene combined with phototherapy or alpha-interferon: Report of eight cases treated in Hospital Nacional Edgardo Rebagliati-Martins, Lima, Peru between 2003 and 2007. Acta Med Peru [Internet]. 2018 Jun. 30 [cited 2024 Dec. 25];25(4):232-5. Available from: https://amp.cmp.org.pe/index.php/AMP/article/view/2643

Most read articles by the same author(s)